Navigation Links
BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
Date:12/10/2013

JERUSALEM, Dec. 10, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that positive preclinical results of BL-8040 (formerly known as BKT-140), for the treatment of Acute Myeloid Leukemia (AML) and other hematological indications, have been presented as a poster at the 55th Annual Meeting of the American Society of Hematology (ASH). The data show that BL-8040 is efficient in inducing the death of AML cancer cells both in vitro and in a humanized mouse model.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

BL-8040 is a novel, potent and selective inhibitor of the CXCR4 chemokine receptor, which is normally activated by the chemokine ligand CXCL12. Both CXCL12 and its receptor, CXCR4, are key players in enabling AML cancer cells to hide and thrive in the bone marrow, and CXCR4 expression in AML patients is associated with poor prognosis. FLT3 mutations are detected in approximately 30% of AML cases and are associated with poor prognosis and a high incidence of relapse in AML patients. In addition, expression of the CXCR4 receptor in FLT3 mutated AML is also correlated with poor outcomes. Accordingly, it is believed that inhibition of CXCR4 may sensitize AML cells toward chemotherapy and FLT-3 targeted therapies.

The data presented in the conference show that BL-8040 directly inhibits AML cell growth and induces cell death, both in cell cultures and in mice engrafted with human AML cells. In addition, the ability of BL-8040 to induce mobilization of AML cells from the bone marrow into the blood circulation enhanced the chemotherapeutic effect of ARA-C (one of the standard-of-care chemotherapies for AML). The effects were even more robust in cells harboring the FLT3 mutation and a synergistic
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
2. BioLineRx Reports Second Quarter 2013 Results
3. BioLineRx Appoints B. J. Bormann to Board of Directors
4. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
5. BioLineRx to Present at 15th International Celiac Disease Symposium
6. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
8. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
11. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... YORK , April 21, 2015 EpiCast ... Summary Sepsis is a life-threatening complication arising from ... the infection damages its own tissues and organs. Anyone ... among children <1 year of age, older ... 2014). Global estimates for the year 2013 showed that ...
(Date:4/21/2015)... DIEGO , 21. April 2015 /PRNewswire/ ... für die quantitative Analyse des Hirnvolumens freut ... einem weltweiten Pharmaunternehmen, bekannt geben zu können. ... leistungsstarken NeuroQuant-Quantifizierungsreports des Hirnvolumens zusammenarbeiten, der die ... Hirnvolumen in Patienten mit multipler Sklerose als ...
(Date:4/21/2015)... 21, 2015 InfuSystem Holdings, Inc. (NYSE MKT: ... related services for the healthcare industry in ... , announces today that it has closed the ... assets of Ciscura Holding Company, Inc., and its subsidiaries.  ... was a privately-held Southeastern regional provider of ambulatory infusion ...
Breaking Medicine Technology:EpiCast Report: Sepsis - Epidemiology Forecast to 2023 2EpiCast Report: Sepsis - Epidemiology Forecast to 2023 3CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an 2InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 2InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 3InfuSystem Announces Acquisition Of Ciscura's Infusion Pump Fleet 4
... Young Innovations, Inc. (NASDAQ: YDNT ) today announced ... 2012.  Sales for the first quarter of 2012 ... in the first quarter of 2011. Income from operations increased 5.3% ... million in the first quarter of 2011. Net income increased 5.6% ...
... April 23, 2012  This week COPAN launched videos ... The new videos were created for the Centers ... to be used in a web based course ... for healthcare providers.  The educational videos show proper ...
Cached Medicine Technology:Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 3Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 4COPAN Produces CDC/Joint Commission Educational Specimen Collection Videos 2
(Date:4/21/2015)... April 21, 2015 The joint venture ... it is opening its first freestanding emergency room later ... Arizona and will be licensed under Dignity Health Arizona ... Health and Adeptus Health joint venture. , Tim Bricker, ... Mercy Gilbert Medical Centers said the new facility will ...
(Date:4/21/2015)... April 21, 2015 Wireless Analytics, ... has been recognized by the Boston Business Journal as ... ranking was announced at a recent event celebrating the ... of the fastest-growing private companies in Massachusetts. , Wireless ... the state that recorded the fastest revenue growth from ...
(Date:4/21/2015)... The report “Dermatitis – ... on the therapeutic development for Dermatitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Dermatitis ...
(Date:4/21/2015)... Edward Avalos, USDA Under Secretary for Marketing ... of the California Department of Food and Agriculture, have ... GrowRIVERSIDE Conference: The Future of Local Food, conference organizers ... nationally known experts intensifies an already strong line-up of ... slated to speak at the June 11-13 event. ...
(Date:4/21/2015)... Wojo Nutrition announces Abe’s ... its healthiest, will carry Wojo Nutrition's lines of single ... Nutrition, they’ve launched a revolution in the vitamin industry ... meet their multifaceted goals. Their line of single serving ... has been specially formulated to be as unique as ...
Breaking Medicine News(10 mins):Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Wojo Nutrition Announces their Lines of Single Serving Liquid Vitamins will be Available for Purchase online at Abesmarket.com Beginning in May 2
... growing evidence that supports an association between atypical fractures of ... without trauma and the use of bisphosphonates, drugs proven ... osteoporosis. While the risk for suffering an atypical femur fracture ... in 1,000 patients after six years of treatment research ...
... HealthDay Reporter , MONDAY, Feb. 6 (HealthDay News) -- ... the first line of defense is lifestyle changes such as ... lifestyle changes don,t get blood sugar levels under control, the ... the first oral treatment that should be given. ...
... Institute at Jefferson joint researchers continue to seek better ... (PJI) in patients following total joint arthroplasty. Their ... in diagnosing urinary tract infections, can also have a ... study built on previous work conducted by Javad Parvizi, ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... the pancreas has sweet-taste receptors -- like those found on ... is a common ingredient in many foods and beverages. Nutrition ... fructose and the new findings might bolster their concerns. ...
... , MONDAY, Feb. 6 (HealthDay News) -- ... linked to a slightly increased risk of death, a ... it should be taken into account by doctors and ... The investigators analyzed the findings of 10 clinical ...
... by Van Andel Research Institute (VARI) scientists enables the ... glioblastoma the most common and most aggressive malignant ... January in the Proceedings of the National Academy ... signaling activation and gene amplification for their susceptibility to ...
Cached Medicine News:Health News:Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half 2Health News:Metformin Preferred Drug for Type 2 Diabetes, Experts Say 2Health News:Metformin Preferred Drug for Type 2 Diabetes, Experts Say 3Health News:Rothman Institute at Jefferson research suggests use of LE strips to diagnose PJI 2Health News:Pancreas May 'Taste' Fructose, Hinting at Links to Diabetes 2Health News:Pancreas May 'Taste' Fructose, Hinting at Links to Diabetes 3Health News:Certain Cancer Drugs May Have Fatal Side Effects: Analysis 2Health News:Discovery predicts patient sensitivity to important drug target in deadly brain cancer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: